新華製藥(000756.SZ)逆市急吐9.5% H股續吐逾2%
受惠人行重啟逆回購操作金額達9,000億人民幣推動,滬指及深成分別由低位2,851及10,551,掉頭續升0.5%及1.1%高收2,890及10,728。不過,上周跑贏科技板塊、因新冠肺炎肆虐行業需求增及醫藥相關板塊均回落,其中國產軟件、人工智能、國產芯片、醫療器械、醫藥生物、免疫治療、病毒防治、獨家藥品、中藥、流感、體外診斷、傳感器及口罩依次跌逾1%-6%。
相關AH股以醫藥板塊表現最差,尤其新華製藥(000756.SZ)曾跌停低見9.05元人民幣,收9.1元,急吐9.5%;本港新華製藥(00719.HK)失守20天線,最低見4.12元,現造4.1元,續吐2.4%,成交218萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.